Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Dec 5, 2008

Premium
Roche Applied Science said this week that it introduced the new xCELLigence RTCA MP instrument two weeks ago. In comparison with the xCELLigence RTCA SP, the new RTCA MP Instrument has a higher throughput capacity and it is more versatile, which enables application on a wider range of experimental set-ups, the company said.
 
The new system features six E-Plate 96 microtiter plates, as opposed to only one in the RTCA SP. Each E-Plate can be individually addressed in independent experiments, to allow a group of researchers to work simultaneously. According to Roche, the first systems have already been delivered to major pharmaceutical companies.
 
The xCELLigence technology features a micro-electronic biosensor built into each well of the standard 96-well E-Plate. A cell which has contact with the sensor changes the electrical impedance between the microelectrodes.
 
Each change in the cell's status — for example, changes in cell adhesion, cytotoxicity, cell proliferation, cell-cell interactions, and morphological changes — leads to changes in the impedance measurements, and can therefore be detected in real time. Labeling of the cells or the use of reporters is not necessary.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.